Johnson & Johnson
DUS:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
DUS:JNJ
Watchlist
Price: 174.42 EUR -1.11%
Market Cap: 420.3B EUR

Operating Margin
Johnson & Johnson

27%
Current
28%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27%
=
Operating Profit
24.9B
/
Revenue
92.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Johnson & Johnson
NYSE:JNJ
495.1B USD
27%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
CH
Roche Holding AG
SIX:ROG
262.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
213B GBP
24%
CH
Novartis AG
SIX:NOVN
211.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
261.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
141.5B USD
29%
FR
Sanofi SA
PAR:SAN
100.1B EUR
24%
No Stocks Found

Johnson & Johnson
Glance View

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27%
=
Operating Profit
24.9B
/
Revenue
92.1B
What is the Operating Margin of Johnson & Johnson?

Based on Johnson & Johnson's most recent financial statements, the company has Operating Margin of 27%.

Back to Top